Author(s):
Sidhant Sharma, Rajdeep Kaur, Jyoti Gupta, Nisha Devi
Email(s):
rajdeepdhaliwal90@gmail.com
DOI:
10.52711/0974-360X.2025.00514 
Address:
Sidhant Sharma2, Rajdeep Kaur1*, Jyoti Gupta3, Nisha Devi4
1Associate Professor, IEC School of pharmacy, IEC University, Baddi, Solan, H.P, 174103.
2Post Graduate Scholar, IEC School of pharmacy, IEC University, Baddi, Solan, H.P, 174103.
3Associate Professor and HOD, IEC School of Pharmacy, IEC University, Baddi, Solan, H.P, 174103.
4Associate Professor, IEC School of Pharmacy, IEC University, Baddi, Solan, H.P, 174103.
*Corresponding Author
Published In:
Volume - 18,
Issue - 8,
Year - 2025
ABSTRACT:
Honokiol is a lignan extracted from Magnolia officinalis, a species of Magnolia commonly found in Japan and is used as conventional drugs throughout Asia. Honokiol shows various types of pharmacological actions such as antidepressant, antimicrobial, anti-tumorigenic, anxiolytic, antithrombotic, analgesic, antispasmodic, neuroprotective and other actions. This study investigated the cardioprotective effects of Magnolia officinalis bark extract in C57 mice. The extract's ability to protect against doxorubicin (3mg/kg, i.p.)-induced cardiotoxicity was evaluated. Body weight, heart weight index, LDH, and CK-MB levels were measured as markers of Cardio protection. Histopathological analysis of heart tissues was also performed. The Magnolia officinalis extract contained various bioactive compounds, including cardiac glycosides, carbohydrates, proteins, alkaloids, glycosides, saponins, and phenols. The extract effectively protected the hearts of mice from doxorubicin-induced cardiotoxicity. Histopathological examinations supported the biochemical findings. The extract's cardioprotective action is likely attributed to its antioxidant properties. The Magnolia officinalis bark extract possesses cardioprotective activity when tested in C57 mice.
Cite this article:
Sidhant Sharma, Rajdeep Kaur, Jyoti Gupta, Nisha Devi. Evaluation of Cardioprotective Activity of Magnolia officinalis Bark Extract against Doxorubicin Induced Toxicity in Mice. Research Journal Pharmacy and Technology. 2025;18(8):3572-8. doi: 10.52711/0974-360X.2025.00514
Cite(Electronic):
Sidhant Sharma, Rajdeep Kaur, Jyoti Gupta, Nisha Devi. Evaluation of Cardioprotective Activity of Magnolia officinalis Bark Extract against Doxorubicin Induced Toxicity in Mice. Research Journal Pharmacy and Technology. 2025;18(8):3572-8. doi: 10.52711/0974-360X.2025.00514 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-8-17
REFERENCES:
1. Wu Y., Liu H., Wang X. Cardio protection of pharmacological postconditioning on myocardial ischemia/reperfusion injury. Life Science. 2021; 264. doi: 10.1016/j.lfs.2020.118628.
2. Amani H., Habibey R., Hajmiresmail S. J., Latifi S., Pazoki-Toroudi H., Akhavan O. Antioxidant nanomaterials in advanced diagnoses and treatments of ischemia reperfusion injuries. Journal of Materials Chemistry B. 2017; 5(48): 9452–9476. doi: 10.1039/C7TB01689A.
3. Nazari A., Sadr S. S., Faghihi M., et al. Vasopressin attenuates ischemia-reperfusion injury via reduction of oxidative stress and inhibition of mitochondrial permeability transition pore opening in rat hearts. European Journal of Pharmacology. 2015; 760: 96–102. doi: 10.1016/j.ejphar.2015.04.006.
4. Shires S. E., Gustafsson A. B. Mitophagy and heart failure. Journal of Molecular Medicine. 2015; 93(3): 253–262. doi: 10.1007/s00109-015-1254-6.
5. Bugger H., Pfeil K. Mitochondrial ROS in myocardial ischemia reperfusion and remodeling. Biochemical et Biophysical Acta (BBA)-Molecular Basis of Disease. 2020; 1866. doi: 10.1016/j.bbadis.2020.165768.
6. Sivaraman V, Yellon D. M. Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. Journal of Cardiovascular Pharmacology and Therapeutics. 2014; 19(1): 83–96. doi: 10.1177/1074248413499973
7. Zhang Y., Qian P., Zhou H., et al. Pharmacological signatures of the exenatide nanoparticles complex against myocardial ischemia reperfusion injury. Kidney and Blood Pressure Research. 2018; 43(4): 1273–1284. doi: 10.1159/000492409
8. Zhang Y. M., Zhang Z. Y., Wang R. X. Protective mechanisms of quercetin against myocardial ischemia reperfusion injury. Frontiers in Physiology. 2020;11: 956. doi: 10.3389/fphys.2020.00956.
9. Liou K. T., Lin S. M., Huang S. S., Chih C. L., Tsai S. K. Honokiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats. Planta Medica. 2003; 69(2): 130–134. doi: 10.1055/s-2003-37707
10. Jaya kumari N. R., Rajendran R. S., Sivasailam A., et al. Honokiol regulates mitochondrial substrate utilization and cellular fatty acid metabolism in diabetic mice heart. European Journal of Pharmacology. 2021; 896. article 173918 doi: 10.1016/j.ejphar.2021.173918.
11. Rauf A., Olatunde A., Imran M., et al. Honokiol: a review of its pharmacological potential and therapeutic insights. Phytomedicine. 2021; 90. article 153647 doi: 10.1016/j.phymed.2021.153647.
12. Tsai S. K., Huang C. H., Huang S. S., Hung L. M., Hong C. Y. Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: influence of L-NAME and aspirin. Pharmacology 1999; 59(5): 227–233. doi: 10.1159/000028324.
13. Tsai S. K., Huang S. S., Hong C. Y. Myocardial protective effect of honokiol: an active component in Magnolia officinalis. Planta Medica. 1996; 62(6): 503–506. doi: 10.1055/s-2006-957957.
14. Zhang B., Zhai M., Li B., et al. Honokiol ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by reducing oxidative stress and apoptosis through activating the SIRT1-Nrf2 signaling pathway. Oxidative Medicine and Cellular Longevity. 2018;2018 doi: 10.1155/2018/3159801.3159801.
15. Wang Y., Zhang Z. Z., Wu Y., Zhan J., He X. H., Wang Y. L. Honokiol protects rat hearts against myocardial ischemia reperfusion injury by reducing oxidative stress and inflammation. Experimental and Therapeutic Medicine. 2013; 5(1): 315–319. doi: 10.3892/etm.2012.766.
16. Pillai V. B., Samant S., Sundaresan N. R. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nature Communications. 2015; 6(1): 6656. doi: 10.1038/ncomms7656.
17. Fried L. E., Arbiser J. L. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxidants and Redox Signaling. 2009; 11(5): 1139–1148. doi: 10.1089/ars.2009.2440.
18. Arora S., Singh S., Piazza G. A., Contreras C. M., Panyam J., Singh A. P. Honokiol: a novel natural agent for cancer prevention and therapy. Current Molecular Medicine. 2012; 12(10): 1244–1252. doi: 10.2174/156652412803833508.
19. Ong C. P., Lee W. L., Tang Y. Q., Yap W. H. Honokiol: A Review of Its Anticancer Potential and Mechanisms. Cancers. 2019; 12(1): 48. doi: 10.3390/cancers12010048.
20. Yuan Y., Zhou X., Wang Y., Wang Y., Teng X., Wang S. Cardiovascular modulating effects of Magnolol and Honokiol, two polyphenolic compounds from traditional Chinese medicine-Magnolia officinalis. Current Drug Targets. 2020; 21(6): 559–572. doi: 10.2174/1389450120666191024175727.
21. 21.Pillai, V. B. et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun 2015; 6: 6656. doi: 10.1038/ncomms7656.
22. Pillai, V. B. et al. Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget. 2017: 101-104. doi: 10.18632/oncotarget 16133.
23. Pillai, V. B. et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun 2015; 6: 6656.doi:10.1038/ncomms 7656.
24. Zhao, C. and Liu, Z. Q. Comparison of antioxidant abilities of magnolol and honokiol to scavenge radicals and to protect DNA. Biochimie 2011; 93: 1755–1760. doi: 10.1016/j. biochip 2011-06.012.
25. Lo, Y. C., Teng, C. M., Chen, C. F., Chen, C. C. and Hong, C. Y. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol 1994; 47: 549–553. doi.10.1016/0006-2952(94)90187-2.
26. Zhang GS, Wang RJ, Zhang HN, Zhang GP, Luo MS, Luo JD. Effects of chronic treatment with honokiol in spontaneously hypertensive rats. Biol Pharm Bull. 2010; 33: 427-431. doi: 10.1248/bpd33.427.
27. Seo MS, Kim JH, Kim HJ, Chang KC, Park SW. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes. Toxicol Appl Pharmacol. 2015; 284: 113-124. doi:10.1016/j. taap2015.02.020.
28. Z. Tan, H. Liu, X. Song, Y. Ling, S. He, Y. Yan. Honokiol post treatment ameliorates Myocardial ischemia/ reprefusion injury by enhancing autophagic flux and Reducing intracellular ROS production. Chem. Biol. Interact 2019; 307: 82-90. doi: 10.1016/jcbi2019.04.032.
29. S. K. Tsai, S.S, Huang, C.Y. Hang. Myocardial protective effect of Honokiol: An active component in Magnolia officinalis. Plants Med.1996; 62: 503-506. doi: 10.1055/s.2006-957957.